Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest

Investigational New Drugs

Volumn 29, Issue 4, 2011, Pages 627-636

  Fu, Jia Ning ^a,b   Li, Jing ^a,b   Tan, Qiang ^b,c   Yin, Han Wei ^a   Xiong, Kun ^a   Wang, Tian Yu ^a   Ren, Xiao Yuan ^a,b   Zeng, Hui Hui ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Cell cycle regulation; Cisplatin; Combination index; Ethaselen; LoVo

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; ETHASELEN; MESSENGER RNA; PROTEIN P21; UNCLASSIFIED DRUG; (1,2 BIS(1,2 BENZISOSELENAZOLONE 3(2H) KETONE))ETHANE; (1,2-BIS(1,2-BENZISOSELENAZOLONE-3(2H)-KETONE))ETHANE; FUSED HETEROCYCLIC RINGS; ORGANOSELENIUM DERIVATIVE; THIOREDOXIN REDUCTASE; TUMOR PROTEIN;

ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL STRAIN; CELL STRAIN LOVO; CHEMOSENSITIVITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; BIOLOGICAL MODEL; CELL DIVISION; CELL PROLIFERATION; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BICYCLO COMPOUNDS, HETEROCYCLIC; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLOW CYTOMETRY; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; ORGANOSELENIUM COMPOUNDS; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 79959688173     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9401-y     Document Type: Article

References (41)

1. Rosenberg B (1999) Platinum complexes for the treatment of cancer: Why the search goes on. In: Lippert B (ed) Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Wiley-VCH, Basel, pp 3-27
2. Yang D, Wang AH-J (1996) Structural studies of interactions between anticancer platinum drugs and DNA. Prog Biophys Mol Biol 66:81-111. doi:10.1016/S0079-6107(96)00017-X (Pubitemid 27161006)
3. Sorenson CM, Eastman A (1988) Influence of cis- Diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient chinese hamster ovary cells. Cancer Res 48:6703-6707 (Pubitemid 19012192)
4. Aguda BD (1999) A quantitative analysis of the kinetics of the G2 DNA damage checkpoint system. Proc Natl Acad Sci 96:11352-11357
5. Eastman A, Schulte N (1988) Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27:4730-4734. doi:10.1021/bi00413a022
6. Bunch RT, Eastman A (1996) Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 2:791-797. doi:10.1016/S0079-6107(96)00017-X (Pubitemid 26168931)
7. Fishel ML, Newell DR, Griffin RJ, Davison R, Wang L-Z, Curtin NJ et al (2005) Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity. J Pharmacol Exp Ther 312:206-213. doi:10.1124/jpet.104.073924 (Pubitemid 40096470)
8. Arnér ESJ (1790) Focus on mammalian thioredoxin reductases - Important selenoproteins with versatile functions. Biochim Biophys Acta (BBA) - General Subjects 1790:495-526. doi:10.1016/j.bbagen.2009.01.014
9. Powis G, Kirkpatrick DL (2007) Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 7:392-397. doi:10.1016/j.coph.2007.04.003 (Pubitemid 47289261)
10. Sasada T, Nakamura H, Ueda S, Sato N, Kitaoka Y, Gon Y et al (1999) Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic Biol Med 27:504-514. doi:10.1016/S0891-5849(99)00101-X (Pubitemid 29408635)
11. Zhao F, Yan J, Deng SJ, Lan LX, He F, Kuang B, Zeng HH (2006) A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines. Cancer Lett 236:46-53. doi:10.1016/j. canlet.2005.05.010
12. Shi CJ, Yu LZ, Yang FG, Yan J, Zeng HH (2003) A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines. Biochem Biophys Res Commun 309:578-583. doi:10.1016/j.bbrc.2003.08.032 (Pubitemid 37083290)
13. Peng ZF, Lan LX, Zhao F, Li J, Tan Q, Yin HW, Zeng HH (2008) A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells. J Zhejiang Univ Sci B 9:16-21. doi:10.1631/jzus.B071605 (Pubitemid 351436993)
14. Deng SJ, Kuang B, Zhou X, Yan J, Zhao F, Jia XY, Zeng HH (2003) BBSKE, 1, 2-[bis(1, 2-benzisoselenazolone-3(2H)-ketone)] ethane, induced cell death in tumor cells. Beijing Da Xue Xue Bao 35:108-109
15. Xing FX, Li S, Ge X, Wang C, Zeng HH, Li D, Dong L (2008) The inhibitory effect of a novel organoselenium compound BBSKE on the tongue cancer Tca8113 in vitro and in vivo. Oral Oncol 44:963-969. doi:10.1016/j.oraloncology.2007.12.001
16. Wang YR, Xiao JJ, Dong XM, Meng SC, Deng SJ, Kuang B, Yan J, Zhao F, Zeng HH (2006) Immune regulating activity of a novel organoselenium compound ethaselen-1 in C57 /BL mice. Beijing Da Xue Xue Bao 38:634-639
17. Lan LX, Zhao F, Wang Y, Zeng HH (2007) The mechanism of apoptosis induced by a novel thioredoxin reductase inhibitor in A549 cells: possible involvement of nuclear factor-κB- dependent pathway. Eur J Pharmacol 555:83-92. doi:10.1016/j.ejphar.2006.10.037 (Pubitemid 46048803)
18. Tan Q, Li J, Yin H, Wang L, Tang W, Zhao F et al (2009) Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo. Invest New Drugs. Mar 7 [Epub ahead of print] doi: 10.1007/s10637-009-9235-7
19. Chou T-C (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681. doi:10.1124/pr.58.3.10
20. 50 values. CompuSyn, Paramus
21. Chou T-C, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
22. Chou T-C (2010) Drug combination studies and their synergy quantification using Chou-Talalay method. Cancer Res 70:440-446. doi:10.1158/0008-5472.CAN-09- 1947
23. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Canc 9:153-67
24. Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9:400-414. doi:10.1038/nrc2657
25. Allen WL, Johnston PG (2005) Role of genomic markers in colorectal cancer treatment. J Clin Oncol 23:4545-4552. doi:10.1200/jco.2005.19.752 (Pubitemid 46196585)
26. Labianca R, Pancera G, Cesana B (1988) Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. Eur J Cancer Clin Oncol 24:1579-1581
27. Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947 (Pubitemid 30644117)
28. Weijl N, Cleton F, Osanto S (1997) Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 23:209-240. doi:10.1016/S0305- 7372(97)90012-8 (Pubitemid 27464149)
29. Levine AJ (1997) P53, the cellular gatekeeper for growth and division. Cell 88:323-331
30. Suganuma M, Kawabe T, Hori H, Funabiki T, Okamoto T (1999) Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation. Cancer Res 59:5887-5891 (Pubitemid 30004945)
31. Allday M, Inman G, Crawford D, Farrell P (1995) DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J 14:4994-5005
32. Lau CC, Pardee AB (1982) Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci 79:2942
33. Yamashita K, Yasuda H, Pines J et al (1990) Okadaic acid, a potent inhibitor of type I and type 2A protein phosphatases, activates cdc2/H1 kinase and transiently induces a premature mitosis-like state in BHK21 cells. EMBO J 9:4331
34. Yu Q, La Rose J, Zhang H, Takemura H, Kohn KW, Pommier Y (2002) UCN-01 inhibits p53 up-regulation and abrogates {gamma}- radiation-induced G2-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 62:5743-5748 (Pubitemid 35204730)
35. Sherr C (1994) G1 phase progression: cycling on cue. Cell 79:551-555
36. Sherr C, Roberts J (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Gene Dev 9:1149-1163. doi:10.1101/gad.9.10.1149
37. Waldman T, Kinzler KW, Vogelstein B (1995) p21 Is Necessary for the p53-mediated G1 Arrest in Human Cancer Cells. Cancer Res 55:5187-5190
38. Olivier M, Theillet C (1996) Cell cycle responses to DNA damage in p53 wt cancer cell lines. Biology of the Cell 88:81. doi:10.1016/S0248-4900(97)86891-8
39. Porter LA, Donoghue DJ (2003) Cyclin B1 and CDK1: nuclear localization and upstream regulators In: Meijer L, Jézéquel A, Roberge M (ed) Progress in Cell Cycle Research, pp 335-47
40. Stewart ZA, Pietenpol JA (2001) p53 signaling and cell cycle checkpoints. Chem Res Toxicol 14:243-263. doi:10.1021/tx000199t (Pubitemid 32238485)
41. Mack PC, Gandara DR, Lau AH, PN L, Edelman MJ, Gumerlock PH (2003) Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother and Pharmacol 51:337-348. doi:10.1007/s00280-003- 0571-6 (Pubitemid 36629812)